著者

伊藤 義彰

出版者

日本神経治療学会

雑誌

神経治療学 (ISSN:09168443)

巻号頁・発行日

vol.38, no.3, pp.356-359, 2021 (Released:2022-01-19)

参考文献数

11

---

In the trials of more versus less statin, the RR per 1.0mmol/L further reduction in LDL cholesterol did not depend on the baseline LDL cholesterol concentration, with significant reductions of 23% in participants who had LDL cholesterol of 2.0–2.5mmol/L reduced further and of 29% in those who had LDL cholesterol lower than 2.0mmol/L (mean 1.71mmol/L) reduced further. “The lower, the better” relation was further confirmed with ezetimibe and PCSK9 inhibitors down to the range of 30mg/dL as the level of LDL–C after treatment. Based on the recent TST trial, target LDL–C level for the prevention of recurrent cardiovascular event may be set below 70mg/dL though Aisan, low body–weight patient, age older than 75 years old may not benefit from the strict control.

著者

伊藤 義彰

出版者

日本神経治療学会

雑誌

神経治療学 (ISSN:09168443)

巻号頁・発行日

vol.39, no.4, pp.435-438, 2022 (Released:2022-12-27)

参考文献数

16

---

Stroke prevention constitutes antithrombotic treatments and risk control. Atherothrombosis may be treated with dual platelet therapy in the acute phase followed by single therapy with additional cilostazol in high risk group. Cardioembolism and paradoxical embolism should be treated with anticoagulants. Direct oral anticoagulants with dose based on age, renal function and body weight has fewer intracranial hemorrhages than warfarin and is recommended as first choice.